patient subgroup...
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
potential COVID-19 treatments - versus placebo - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.80 [0.70, 0.91]< 1 48% 33 studies (33/-) 100.0 % some concern critical moderate crucial - death or transfer to ICU 0.73 [0.51, 1.05]< 1 0% 4 studies (4/-) 95.6 % low not evaluable high crucial - deaths 0.80 [0.72, 0.89]< 1 37% 70 studies (70/-) 100.0 % some concern critical moderate crucial - deaths (time to event analysis only) 0.74 [0.62, 0.87]< 1 27% 17 studies (17/-) 100.0 % some concern low moderate crucial - clinical deterioration 0.71 [0.55, 0.91]< 1 60% 15 studies (15/-) 99.6 % low low high important - clinical improvement 1.12 [1.06, 1.19]> 1 8% 25 studies (25/-) 100.0 % some concern low moderate important - clinical improvement (14-day) 1.20 [1.07, 1.34]> 1 0% 7 studies (7/-) 99.9 % low not evaluable high important - clinical improvement (28-day) 1.30 [1.10, 1.52]> 1 1% 10 studies (10/-) 99.9 % some concern low moderate important - clinical improvement (7-day) 0.94 [0.84, 1.06]> 1 0% 6 studies (6/-) 16.5 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.11 [1.05, 1.18]> 1 0% 18 studies (18/-) 100.0 % some concern low moderate important - death or ventilation 0.74 [0.64, 0.84]< 1 0% 15 studies (15/-) 100.0 % some concern low moderate important - hospital discharge 1.03 [0.98, 1.08]> 1 0% 19 studies (19/-) 89.9 % low low high important - hospitalization 0.67 [0.20, 2.17]< 1 63% 4 studies (4/-) 74.9 % low not evaluable high important - mechanical ventilation 0.86 [0.68, 1.09]< 1 13% 16 studies (16/-) 89.2 % some concern low moderate important - mechanical ventilation (time to event analysis only) 0.77 [0.31, 1.90]< 1 0% 2 studies (2/-) 71.5 % some concern not evaluable moderate important - Recovery (time to event analysis only) 1.02 [0.81, 1.28]> 1 0% 1 study (1/-) 56.7 % NA not evaluable important - viral clearance 1.07 [0.78, 1.48]> 1 65% 6 studies (6/-) 66.3 % low not evaluable high important - viral clearance (time to event analysis only) 1.20 [0.69, 2.08]> 1 75% 4 studies (4/-) 74.3 % some concern not evaluable moderate important - viral clearance by day 14 4.10 [1.12, 14.99]> 1 0% 1 study (1/-) 98.3 % NA not evaluable important - viral clearance by day 7 0.92 [0.78, 1.08]> 1 0% 3 studies (3/-) 15.4 % low not evaluable high important - ICU admission 0.68 [0.50, 0.93]< 1 0% 10 studies (10/-) 99.3 % some concern low moderate non important - off oxygenation 0.88 [0.43, 1.80]> 1 11% 2 studies (2/-) 36.0 % some concern not evaluable moderate non important - recovery 1.10 [0.97, 1.26]> 1 42% 9 studies (9/-) 92.7 % low serious high non important - 00 AE leading to drug discontinuation 2.43 [0.79, 7.45]< 1 0% 1 study (1/-) 6.0 % NA not evaluable important - composite safety outcome 1.56 [0.78, 3.11]< 1 0% 1 study (1/-) 10.3 % NA not evaluable important - related AE (TRAE) 1.26 [0.14, 11.07]< 1 0% 2 studies (2/-) 41.9 % some concern not evaluable moderate important - serious adverse events 0.89 [0.77, 1.04]< 1 11% 19 studies (19/-) 93.1 % some concern low moderate important - superinfection 0.74 [0.49, 1.11]< 1 57% 3 studies (3/-) 92.9 % low not evaluable high important - adverse events 1.31 [0.94, 1.81]< 1 65% 18 studies (18/-) 5.5 % some concern low moderate non important - deep vein thrombosis 0.62 [0.23, 1.64]< 1 0% 2 studies (2/-) 83.1 % some concern not evaluable moderate non important - elevated liver enzymes 0.58 [0.34, 0.97]< 1 6% 2 studies (2/-) 98.1 % some concern not evaluable moderate non important - hyperbilirubinemia 0.97 [0.48, 1.93]< 1 0% 2 studies (2/-) 53.8 % low not evaluable high non important - pulmonary embolism 0.82 [0.20, 3.29]< 1 0% 2 studies (2/-) 61.1 % some concern not evaluable moderate non important - renal impairment 1.02 [0.64, 1.61]< 1 0% 2 studies (2/-) 47.2 % some concern not evaluable moderate non important - severe adverse events 1.21 [0.02, 64.67]< 1 0% 1 study (1/-) 46.4 % NA not evaluable non important -
LoD: level of statistical demonstration:
